Opinion: Writer sees biotechs entering 2005 with "good momentum"

12/30/2004 | TheStreet.com

Although 2004 is replete with "blowups" of biotechnology companies, the sector is entering 2005 with good momentum, the most heavily capitalized staying stronger than small-cap firms, according to a senior writer at TheStreet.com. U.S. cutbacks in Medicare reimbursements next year could lead to a trend change in drug usage and affect biotech companies such as Amgen, Genentech and Biogen Idec.

View Full Article in:

TheStreet.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA